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Abstract
OBJECTIVE—The primary cervical cancer screening strategy for women over age 30 is high-
risk human papillomavirus (HPV) testing combined with Papanicolaou (Pap) testing (cotesting) 
every 5 years. This combination strategy is a preventive service that is required by the Affordable 
Care Act to be covered with no cost-sharing by most health insurance plans. The cotesting 
recommendation was made based entirely on prospective data from an insured population that 
may have a lower proportion of women with HPV positive and Pap negative results (ie, discordant 
results). The discordant group represents a very difficult group to manage. If the frequency of 
discordant results among underserved women is higher, health care providers may perceive the 
cotesting strategy to be a less favorable screening strategy than traditional Pap testing every 3 
years.
STUDY DESIGN—The Centers for Disease Control and Prevention’s Cervical Cancer Study was 
conducted at 15 clinics in 6 federally qualified health centers across Illinois. Providers at these 
clinics were given the option of cotesting for routine cervical cancer screening. Type-specific 
HPV detection was performed on residual extracts using linear array.
RESULTS—Pap test results were abnormal in 6.0% and HPV was positive in 7.2% of the 
underserved women screened in this study (mean age, 45.1 years). HPV prevalence decreased with 
age, from 10.3% among 30- to 39-year-olds to 4.5% among 50- to 60-year-olds. About 5% of the 
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women had a combination of a positive HPV test and normal Pap test results; HPV 16/18 was 
identified in 14% of discordant women.
CONCLUSION—The rate of discordant results among underserved women was similar to those 
reported throughout the US in a variety of populations. Typing for HPV 16/18 appears to assist in 
the management in a small proportion of women with discordant results.
Keywords
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Since 2003, in the United States, cervical cancer screening with human papillomavirus 
(HPV) and Papanicolaou (Pap) tests (“cotesting”) has been recommended by the American 
College of Obstetricians and Gynecologists and the American Cancer Society.1,2 In 2012, 
the United States Preventive Services Task Force3 endorsed cotesting every 5 years as an 
alternative screening strategy to Pap-testing alone every 3 years among women 30 to 65 
years of age. The American Cancer Society and American College of Obstetricians and 
Gynecologists made similar recommendations, although they deemed cotesting as the 
preferred strategy.4,5 However, provider and patient surveys have indicated that cotesting 
and the increase in screening intervals have not been widely adopted; in fact, lengthening 
screening intervals beyond annual screening is uncommon.6-9
In addition to potentially improving acceptability and compliance with appropriate 
lengthened screening intervals, an important need has been to define the optimal follow-up 
of women who have HPV-positive and Pap-negative results (from here on, this will be 
called discordant results). Women with discordant results have a low prevalence of cervical 
intraepithelial neoplasia of grade 2 or worse (CIN 2+).10 In 2006, the American Society for 
Colposcopy and Cervical Pathology (ASCCP) published guidelines recommending that 
these women either be retested with both HPV and Pap tests in a year, or tested for HPV 16 
and 18 (using a test approved by the US Food and Drug Administration) and directed to 
colposcopy if results are positive.11,12 According to data from a large managed care 
organization that includes over half a million women, followed prospectively, approximately 
4% of women 30 and older can be expected to have discordant results.13 However, there is 
concern that data from a managed care population may not be generalizable to low-income, 
underinsured women. Moreover, if the frequency of discordant results among underserved 
women is higher, health care providers may perceive the cotesting strategy to be less 
favorable than traditional Pap testing every 3 years.
Our Centers for Disease Control and Prevention’s (CDC) Cervical Cancer Study (referred to 
as the Cx3 Study) offered a unique opportunity to examine the performance of cotesting in a 
cohort of underserved women presenting to federally qualified health centers (FQHCs) for 
routine cervical cancer screening. We also sought to compare the results of HPV type-
specific testing in this population of women with that of other populations, to estimate the 
effect of type-specific HPV testing on referral to colposcopy. This population of women is 
of increased concern when determining optimal management strategies to ensure proper 
follow-up for those at highest risk of cervical cancer.
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MATERIALS AND METHODS
Participants
The data for this study were obtained from women, recruited between Sept. 2009 and May 
2011 as part of CDC’s Cx3 Study. The study was conducted in 15 clinics associated with 6 
FQHCs serving low-income women in Illinois. FQHCs provide comprehensive primary 
health care services to medically underserved communities and vulnerable populations in 
high-need areas across the United States.14 Women between the ages of 30 and 60 who were 
being seen in one of the FQHCs for a routine screening Pap test were identified through 
medical chart review by clinic staff. This group had no abnormal Pap test results in the 
preceding year survey, no history of cervical cancer, no record of being HIV positive, and 
no hysterectomy. They were invited to participate in our study when they arrived at the 
clinic for their routine visit. Further details on study design can be found in Benard et al.15 
This study was approved by CDC’s Institutional Review Board. Informed consent was 
obtained from all study participants.
Two samples of exfoliated cervical cells were collected during the pelvic examination after 
visualization of the cervix. The first sample was collected per clinic protocol for routine Pap 
tests (either liquid or conventional) using the Bethesda system for reporting.16 The second 
sample was collected with the Digene Cervical Sampler (Qiagen Inc., Valencia, CA) and 
placed in specimen transport media (STM; Qiagen) for high-risk HPV testing (Hybrid 
Capture 2, HC2; Digene, Gaithersburg, MD). The STM specimens were stored and shipped 
to CDC at ambient temperature within 1 week of collection.
Laboratory
Specimens received at CDC were stored at 4°C and processed within 1 week of receipt. 
High-risk HC2 testing was performed on 250 μL aliquot, according to the manufacturer’s 
specification. A positive result indicates the presence of 1 or more of the 13 high-risk types: 
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68. A second 200 μL aliquot was treated with 
Proteinase K at 65°C to lyse cells and the DNA from lysate was purified using the 
automated Chemagic Magnetic Separation Module 1 (PerkinElmer chemagen Technologie 
GmbH, Baesweiler, Germany) with the ViralNA/gDNA kit (Chemagen). The resulting 
extract (100 μL total volume) was tested immediately or stored at −20°C. Water blanks were 
processed through all laboratory steps as contamination control.
All DNA extracts were tested with the Research Use Only Linear Array genotyping assay 
(Roche Diagnostics, Indianapolis, IN). This assay uses HPV L1 consensus polymerase chain 
reaction (PCR) with PGMY09/11 primers and consensus PCR with β-globin primers as an 
internal control for amplification and cellular DNA. The typing strips include probes for 37 
different HPV types (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, XR(52), 53, 54, 55, 56, 
58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, 89, IS39). There are 14 
specific high-risk types examined in this assay: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 
66, 68. The manufacturer’s protocol was modified to use 10 μL extract in the 100 μL PCR 
reaction and automated hybridization and wash steps with Bee Blot instrument (Bee 
Robotics, Caernafon, UK). Because HPV52 is detected with XR probe that cross-hybridizes 
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with HPV 33, 35, and 58, all XR- high-risk positive samples with 1 or more cross-
hybridizing types present were tested using a type-specific HPV 52 quantitative PCR.17 We 
had 15 samples that were considered negative for high-risk HC2, but these were positive for 
high risk by linear array. We excluded these in the analysis that was based on the 
assumption that HC2 would be the first test used. Samples negative for all HPV types and β-
globin were considered inadequate and were omitted from further analysis.
Analysis
We analyzed baseline data from the 2246 women enrolled in the study who had both HPV 
and Pap testing. Pap test results defined as positive included atypical squamous cells of 
undetermined significance. Atypical squamous cells cannot exclude high-grade squamous 
intraepithelial lesion, low-grade squamous intraepithelial lesion, high-grade squamous 
intraepithelial lesion, squamous cell carcinoma, and atypical glandular cells (atypical 
glandular cells of undetermined significance, adenocarcinoma). Results for cotesting 
included negative (HPV negative and Pap normal), discordant (HPV positive and Pap 
normal) or positive (HPV positive and Pap positive; HPV negative and Pap positive). 
Binomial exact 95% confidence intervals (CIs) were calculated for Pap and HPV results 
prevalence. Typing results are reported only for those samples that were HC2 HPV-positive. 
Other factors that were collected included the woman’s age and clinic location, including 
Chicago area and nonChicago area (ie, southern Illinois and mid-Illinois). Prevalence ratios 
(HPV/Pap) with 95% CIs were calculated to show the relative contribution of HPV to Pap 
for screening positive by cotesting. McNemar’s χ2 test was used to test for statistical 
differences (P < .05) for testing HPV-positive vs testing Pap-positive for all women and 
within 10-year age groups. Logistic regression was used to test the statistical differences of 
overall HPV positivity (HPV positive vs HPV negative) and discordant result (HPV 
negative and Pap negative vs all other categories combined) by 10-year age groups. The 50- 
to 60-year-old age group was included as the reference category. We used Stata version 12.1 
(StataCorp, College Station, TX) for statistical analyses.18
RESULTS
For the 2246 women enrolled in the study, the mean age was 45.1 years (Table 1). Two-
thirds of the women were from Chicago. Two-thirds of the samples used liquid-based 
cytology. Overall, the HPV test result was positive in 7.2% (95% CI, 6.2–8.4%; n = 162) of 
the women; while 6.0% (95% CI, 5.0–7.0%; n = 134) had a positive Pap test result. Most 
(89.1%, 95% CI, 87.8–90.4%; n = 2002) were cotest negative and 4.9% (95% CI, 4.0–5.9%; 
n = 110) had discordant results (HPV positive and Pap negative results).
The various combinations of HPVand Pap test results are presented in Table 2. In general, 
the percentage of Pap-test results considered abnormal remained relatively constant across 
age categories. However, the percentage of HPV-positive tests decreased from 10.3% 
among women aged 30 to 39 years to 4.5% among those aged 50 to 60 years (odds ratio, 
2.43; P < .001). The prevalence of discordant cotest results decreased by age group with a 
higher rate for women aged 30 to 39 (6.5%) than among women aged 50 to 60 years (2.9%) 
(odds ratio, 2.2; P = .003).
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Figure 1 shows the HPV genotype distribution among HPV-positive (HC2) women with Pap 
positive and negative results. Among women with positive Pap results (n = 52), the most 
common genotypes were HPV 16 (23%), HPV 31 (17%), HPV 52 (17%), HPV 18 (12%), 
and HPV 58 (12%). Among women with negative Pap results (n = 110), the most frequent 
HPV genotypes were HPV 31 (11%), HPV 59 (9%), HPV 51 (8%), and HPV 52 (8%). HPV 
16 and 18 represented 7% and 6% respectively.
We used the information from this study to project the percentage of women who would 
require more vigilant surveillance if current management guidelines from the ASCCP were 
followed (Figure 2). According to our data, approximately 5% of women aged 30 to 60 
years would have discordant results and would require further workup. If genotyping were 
conducted for all of these women, most (86%) would not be triaged for immediate 
colposcopy. HPV results in the cotest discordant group were 5.5% HPV 16 only, 1.8% HPV 
16 with at least 1 other high-risk HPV type, 5.5% HPV 18 only, 0.9% HPV 18 with at least 
1 other high-risk HPV type.
DISCUSSION
In developing both cervical cancer screening and management guidelines, disease risk 
determinations are often based on longitudinal studies of women in settings such as 
managed care organizations, where women have easy access to care. There is general 
concern that data derived from such populations may be different from data on underserved 
women. We found that the discordance rates were consistent with a recent large-scale study 
in Kaiser Permanente Northern California (Berkeley, CA), a health maintenance 
organization,13 with 6.3% (compared with 7.2% in our study) HPV positive and 4.0% 
(compared with 4.9% in our study) discordant rate (HPV positive/Pap negative). These 
findings suggest that the recommended guidelines for cervical cancer screening and 
management can be followed, even in this vulnerable population.
Higher confidence and use of cotesting in cervical screening is supported primarily by the 
low risk of CIN3+ among women whose results are negative for both tests and in whom 
screening intervals may be substantially lengthened.10 A major limitation of HPV testing is 
that benign infections likely to clear up are common enough to lead to a low predictive value 
for a single positive test. In other words, most discordant women have a low risk of 
developing cancer.10 Immediate referral of all of these women for colposcopy could easily 
triple referral rates to colposcopy and may represent excessive intervention, given the low 
risk for imminent cancer in these women. However, the 5-year cumulative risk of CIN 3+ 
among women with discordant results is considerably higher than after a Pap-negative result 
alone.19 Therefore, the new ASCCP guidelines recommend following women who are HPV-
positive/Pap-negative with a repeat cotest at 1 year.12
An alternative management strategy for discordant women would be to perform HPV 16/18 
typing with immediate colposcopy referral for women with positive results and 1-year 
follow-up cotesting for women with negative results. We found approximately 14% of HPV-
positive/Pap-negative women were positive for HPV 16/18 and would have required 
immediate colposcopy. This would mean that in a group of 2000 cotested women, 100 
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would have discordant results. A clinic would incur the cost of the HPV 16/18 test for all 
100 women to identify 14 for colposcopy; based on results from the ATHENA trial,20 1 to 2 
women among these 14 could be expected to be identified as having CIN 3+. The remaining 
86 who are HPV 16/18 negative would have a lower risk of CIN 3+, though apparently not 
low enough to return to routine screening; recommendations are for these women to return 
the following year for repeat cotesting. Another concern is short-term anxiety of having a 
positive HPV test with recommendations to wait a year before intervening.21
These findings help inform the larger Cx3 Study designed to understand the barriers 
associated with cotest use and the extension of the interval between screenings in the 
underserved population8,9 by providing information on the cotest results and the number that 
may require additional management. To improve cervical cancer screening among medically 
underserved women, Congress authorized the CDC to develop the National Breast and 
Cervical Cancer Early Detection Program (NBCCEDP) in 1990.22 The NBCCEDP is a 
comprehensive public health program that helps low-income, under-, and uninsured women 
gain access to breast and cervical screening services. Before the 2012 revision to the United 
States Preventive Services Task Force screening guidelines, the NBCCEDP reimbursed 
providers for the HPV test for management of abnormal Pap results, but not as a cotest. In 
July 2012, CDC adopted these new cotesting guidelines, but the implications of the extended 
screening interval and the management strategies have not been fully explored. Currently, 
the programs are reimbursing for repeating the cotest in a year, but not for genotyping. The 
ASCCP guidelines state that the additional genotyping is an alternate strategy, but do not 
report a preference.12 More modeling and cost-effectiveness studies may be done on the 
strategy of HPV 16/18 testing, as this would be very useful information for the NBCCEDP 
and other programs that treat low-income women.
This study has several strengths, including enrollment of over 2000 low-income, un-, and 
underinsured patients in the setting of FQHCs across a diverse population of urban and rural 
clinics in Illinois. As a demonstration study in 1 state, our results may not be generalizable 
to other settings. In addition, the number of women with abnormal results is small; 
extending the study to more sites would improve the estimate of the discordant cotests in 
this population. However, when we examined the cytological outcomes of the study 
population in Illinois, it was similar to the NBCCEDP cytologic distribution (the HPV data 
were not available for comparison). An additional limitation was that the baseline data 
provides only cross-sectional HPV and Pap test results with no histologic outcomes. 
However, this study is collecting medical chart data as the final end point to be able to link 
the testing results to the clinical outcomes.
COMMENT
The rate of discordant cotesting results in this study of underserved women was similar to 
rates reported throughout the US in various populations, including those who are insured. 
This is important reassurance for providers who might have been unsure if they should 
follow national guidelines in this vulnerable population, because most of the data generated 
for the recommendations were based solely on managed-care populations.
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FIGURE 1. Percent distribution of high risk genotypesa by Pap test results (Cx3 Study, n [ 162)
Pap+ includes atypical squamous cells of undetermined significance, low grade squamous 
intraepithelial lesion, high grade squamous intraepithelial lesion, atypical glandular cells of 
undetermined significance, atypical glandular cells, adenocarcinoma; Pap− includes Pap 
negative/normal.
Cx3 Study, Centers for Disease Control and Prevention’s Cervical Cancer Study; HPV, 
human papillomavirus test; Pap, Papanicolaou test.
aHigh risk genotypes were assessed for 14 high-risk types using Roche Linear Array (Roche 
Diagnostics, Indianapolis, IN) among all samples that initially tested positive for pooled 
HPV (Hybrid Capture 2 [HC2; Digene, Gaithersburg, MD] HPV positive).
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FIGURE 2. Cx3 Study data with current national algorithmsa
This management algorithm for discordant results shows the percentage of women who 
would have various test results and require further workup using data from the study and 
may inform the CDC program.
Cx3 Study, Centers for Disease Control and Prevention’s Cervical Cancer Study; HPV, 
human papillomavirus test; Pap, Papanicolaou test; s.d., standard deviation.
aAmerican Society of Colposcopy and Cervical Pathology (ASCCP) National Algorithms.
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TABLE 1
Demographics and laboratory test results, CDC Cervical Cancer Study 2009-2011
Demographic Category n %
Age at enrollment,
by 5-y age category
30-34 149 6.6
35-39 471 21.0
40-44 473 21.1
45-49 468 20.8
50-54 385 17.1
55-60 300 13.4
Total 2246 100.0
Age at enrollment, mean (SD) 45.1 (7.6)
Clinic is located in Chicago No 772 34.4
Yes 1474 65.6
Total 2246 100.0
Laboratory tests
 Pap test type Liquid 1466 65.3
Conventional 768 34.2
Not reported 12 0.5
 Total 2246 100
 Pap results Negative 2112 94.0
ASC-US 95 4.2
LSIL 25 1.1
ASC-H 4 0.2
HSIL 5 0.2
AGUS 3 0.1
AGC 1 0.04
Adenocarcinoma 1 0.04
 Total 2246 100.0
 Pap resultsa Negative 2112 94.0
Positive 134 6.0
 Total 2246 100
 HPV resultsb Negative 2084 92.8
Positive 162 7.2
 Total 2246 100
Pap and HPV combinations Pap− / HPV− 2002 89.1
Pap+ / HPV − 82 3.7
Pap− / HPV+ 110 4.9
Pap+ / HPV+ 52 2.3
2246 100.0
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AGC, atypical glandular cells; AGUS, atypical glandular cells of undetermined significance; ASC-H, atypical squamous cells cannot exclude high-
grade; ASC-US, atypical squamous cells of undetermined significance; HPV, human papillomavirus test; HSIL, high grade squamous intraepithelial 
lesion; LSIL, low grade squamous intraepithelial lesion; Pap, Papanicolaou test; SD, standard deviation.
aNegative includes within normal limits and negative for intraepithelial lesion or malignancy; Positive includes ASC-US, LSIL, HSIL, AGUS, 
AGC, adenocarcinoma;
bNegative includes HPV negative; positive includes HPV positive.
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